Titre : | A controlled trial of buprenorphine treatment for opium dependence: the first experience from Iran (2002) |
Titre traduit : | (Essai contrôlé de traitement de la dépendance aux opiacés par la buprénorphine : première expérience irannienne) |
Auteurs : | J. AHMADI |
Type de document : | Article : Périodique |
Dans : | Drug and Alcohol Dependence (Vol.66, n°2, 2002) |
Article en page(s) : | 111-114 |
Note générale : |
Drug and Alcohol Dependence, 2002, 66, (2), 111-114 |
Langues: | Français |
Discipline : | TRA (Traitement et prise en charge / Treatment and care) |
Mots-clés : |
Thésaurus mots-clés OPIACES ; BUPRENORPHINE ; DEPENDANCE ; TRAITEMENT DE MAINTENANCE ; RETENTION ; EVALUATIONThésaurus géographique IRAN |
Résumé : |
ENGLISH : Aims: To evaluate the effect of a 4 mg/day sublingual dose of buprenorphine in the maintenance treatment of opium dependence in comparison with a 1 mg/day dose over an 18-week treatment period. As a secondary objective, the results were determined concurrently for subjects treated with a 2 mg/day dose. Design: Subjects were assigned randomly to three dosage groups. Participants: 330 consecutive (320 men and 10 women) opium addicts who met the DSM-IV criteria for opioid dependence and were seeking treatment. Intervention: Subjects received a 1, 2 or 4 mg/day dose of buprenorphine and were treated in an outpatient clinic where they also received a weekly 1-hour clinical counseling session. Measurements: Addiction Severity Index, retention in treatment, and illegal opioid use as determined by random urine testing. Findings: The mean age was 37.5 years (SD = 11.4, range 19-72). Overall, 194 (58.8%) of the patients completed the 18 week study. Completion rates by dosage groups were 47.3% for the 1 mg group, 58.2% for the 2 mg group and 70.9% for the 4 mg group (X2 = 12,7, df = 2, P = 0.0017). Conclusions: The results support the efficacy and safety of buprenorphine for opium addiction and suggest that an adequate dose of buprenorphine would help to increase the success rate. (Author's abstract.) |
Note de contenu : | tabl. |
Domaine : | Drogues illicites / Illicit drugs |
Refs biblio. : | 18 |
Affiliation : |
Dept. Psychiatr., Shiraz Univ. Med. Sci., PO Box 71345-1416, Shiraz Iran. Iran. |
Numéro Toxibase : | 803955 |
Centre Emetteur : | 08 CAS Strasbourg |
Cote : | Abonnement |
Accueil